Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency clinical trials

Explore recruiting ectonucleotide pyrophosphatase phosphodiesterase 1 enpp1 deficiency clinical trials.

Recruiting ectonucleotide pyrophosphatase phosphodiesterase 1 enpp1 deficiency studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

The ENERGY 3 Study: A Randomized, Controlled, Open-Label, Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Children with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

France, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

The ENERGY 2 Study: An Open-Label Phase 3 Study to Evaluate the Efficacy and Safety of INZ-701 in Infants with Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) Deficiency

Hungary, France, Sweden, Italy, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

The ENERGY Study: An Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INZ-701 in Infants with Ectonucleotide Pyrophosphatase/ Phosphodiesterase 1 (ENPP1) Deficiency or ATP-binding Cassette Sub-family C Member 6 (ABCC6) Deficiency

Spain

Human Pharmacology (Phase I)- Other EU CTIS Study details

The ADAPT Study: An Open-Label, Long-term Safety Study of INZ-701 in Patients with ENPP1 Deficiency and ABCC6 Deficiency

Germany, France

Therapeutic exploratory (Phase II) EU CTIS Study details

Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency trials by city

Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency in Toronto Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency in Vancouver Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency in Montreal Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency in Calgary Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency in Edmonton Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency in Ottawa Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency in Winnipeg Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency in Quebec City Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency in Hamilton Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency in Kitchener Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency in London Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency in Halifax Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency in New York Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency in Los Angeles Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency in Chicago Ectonucleotide Pyrophosphatase Phosphodiesterase 1 Enpp1 Deficiency in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease